Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to study the effect of SOT in highlanders with high altitude pulmonary hypertension (HAPH) who permanently live \>2500m on pulmonary arterial pressure (PAP) assessed at 3200 m.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Effects of Iron on Lung Blood Pressure at High Altitude

NCT00960921

Hypertension, Pulmonary

WITHDRAWN PHASE2

HighCycle Study: Acetazolamide, High Altitude and Plasma Volume

NCT07118462

High Altitude Effects High Altitude Hypoxia Acute Mountain Sickness (AMS) +2 more

RECRUITING PHASE4

Treatment of High Altitude Polycythemia by Acetazolamide

NCT00424970

High Altitude Polycythemia

COMPLETED PHASE4

HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men

NCT06498505

High Altitude

RECRUITING PHASE4

HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men

NCT06499727

Acute Mountain Sickness

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA (Tricuspid Regurgitation Pressure Gradient) \>30 mmHg will be recruited for this project. Highlanders permanently living at HA \>2500 m will have echocardiografy to assess PAP near their living altitude in Aksay at 3200 m with and without 10L/min supplemental oxygen therapy (SOT) via face mask.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Altitude Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Each highlander with HAPH will perform a echocardiography with and without SOT according to a cross-over design

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ambient air

Highlanders with HAPH will perform the echocardiography on ambient air at 3200m

Group Type ACTIVE_COMPARATOR

Echocardiography

Intervention Type OTHER

Echocardiography will be performed according to clinical standards

10 L/min SOT through face mask

Supplemental oxygen therapy (SOT) at 10 L/min will be provided via face mask from oxygen concentrators

Group Type EXPERIMENTAL

Echocardiography

Intervention Type OTHER

Echocardiography will be performed according to clinical standards

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Echocardiography

Echocardiography will be performed according to clinical standards

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Permanently living \>2500 m
* HAPH diagnosed with a minimum RV/RA of 30 mmHg assessed by echocardiography at an altitude of 3200 m
* Written informed consent

Exclusion Criteria

* Highlanders who cannot follow the study investigations,
* Patients with moderate to severe concomitant lung disease (FEV1\<70% or forced vital capacity \<70%), severe parenchymal lung disease, heavy smoking \>20 cigarettes/day or \>20 pack-years.
* Coexistent unstable systemic hypertension or coronary artery disease that required adjustment of medication within the last 2 months
* Regular use of medication that affects control of breathing (benzodiazepines, opioids, acetazolamide)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No